

Appendix 9. Essential Reference Organisms and Toxins*

Genus	Species/Serotype	Strain	Source	Additional Recommended Species/Strains			Exclusivity Species
				Species	Strain/Serotype	Source	
<i>Aeromonas</i>	<i>A. hydrophila</i> <i>A. hydrophila</i>	ATCC® 49140™ ATCC® 7965™	ATCC® ATCC®				
<i>Bacillus anthracis</i>	<i>B. anthracis</i> <i>B. anthracis</i>	AMC strain Ames strain	BEI Resources BEI Resources				
Controlled Access	<i>B. anthracis</i> <i>B. anthracis</i>	Davis Kruger B1	BEI Resources BEI Resources				
<i>Bacillus cereus</i>	<i>B. cereus</i> <i>B. cereus</i> <i>B. cereus</i> <i>B. cereus</i> <i>B. cereus</i>	ATCC® 13061™ ATCC® 13061™ ATCC® 10876™ enterotoxigenic producing strains - FDA TJL-14 emetic toxin producers	ATCC® ATCC® ATCC® FDA Pending final method research				
<i>Brucella</i>	<i>B. abortus</i> (CO2 dependent and independent) <i>B. canis</i>		BEI Resources BEI Resources				
Controlled Access	<i>B. melitensis</i> <i>B. suis</i>		BEI Resources BEI Resources				
<i>Campylobacter</i>	<i>C. fetus</i> subsp. <i>fetus</i> <i>C. jejuni</i> subsp. <i>jejuni</i> <i>C. coli</i> <i>C. upsaliensis</i> <i>C. jejuni</i> subsp. <i>venerealis</i> <i>C. lari</i> <i>C. jejuni</i> subspecies <i>doylei</i> <i>C. jejuni</i> subspecies <i>jejuni</i> <i>C. jejuni</i> subpecies <i>jejuni</i>	ATCC® 15296™ ATCC® 33291™ ATCC® 43478™ ATCC® 19438™ ATCC® 35222™ NCTC 11457 ATCC® 49351™ NCTC 11924 CIP 702 NCTC 11168	ATCC® ATCC® ATCC® ATCC® ATCC®/ NCTC ATCC®/ NCTC BEI Resources BEI Resources				
<i>Clostridium</i>	<i>C. perfringens</i> <i>C. perfringens</i> Hobbs serotype 2 <i>C. perfringens</i> Hobbs serotype 3 <i>C. perfringens</i> Hobbs serotype 13 <i>C. perfringens</i> <i>C. botulinum</i> Type A <i>C. botulinum</i> Type B <i>C. botulinum</i> Type E <i>C. botulinum</i> Type F <i>C. butyricum</i> Type E <i>C. argentinense</i> Type G	ATCC® 3624™ NCTC 8238 NCTC 8239 NCTC 10240 ATCC® 12919™ No longer available from ATCC® or by reference strain number former ATCC® 25763™ No longer available from ATCC® or by reference strain number former ATCC® 17848™ No longer available from ATCC® or by reference strain number former ATCC® 9564™ No longer available from ATCC® or by reference strain number former ATCC® 35415™ No longer available from ATCC® or by reference strain number former ATCC® 43755™ No longer available from ATCC® or by reference strain number former ATCC® 27322™	ATCC(r) ATCC® ATCC® ATCC® ATCC® BEI Resources BEI Resources BEI Resources BEI Resources BEI Resources former ATCC® 25763™ former ATCC® 17848™ former ATCC® 9564™ former ATCC® 35415™ former ATCC® 43755™ former ATCC® 27322™	Requires Export permit outside of the US Requires Export permit outside of the US			
<i>Coxiella burnetii</i>							
<i>Cryptosporidium</i>	<i>C. parvum</i> (For DNA only) <i>C. parvum</i> (Oocyst) <i>C. parvum</i> (bovine genotype) <i>C. hominis</i>	PRA-67D, IOWA strain IOWA strain IOWA strain	ATCC® or Waterborne, Inc. Bunch Grass Farm				
<i>Cyclospora</i>	<i>C. cayetanensis</i>	Any isolates from feces from naturally infected individuals. Currently, no isolate or strain is maintained in a laboratory.					
<i>Enterobacter sakazakii</i>	<i>E. sakazakii</i> <i>E. aerogenes</i>	ATCC® 51329™ ATCC® 13048™	ATCC® ATCC®				
<i>Escherichia coli</i>	<i>E. coli</i> Biotype1 <i>E. coli</i> Biotype1 <i>E. coli</i> <i>E. coli</i> <i>E. coli</i> O157:H7 (toxin negative)	ATCC® 11775™ ATCC® 51813™ ATCC® 25922™ ATCC® 8739™ ATCC ® 43888™	ATCC® ATCC® ATCC® ATCC® ATCC®				
(Pathogenic)	<i>E. coli</i> O157:H7 (toxin positive) VT1 or VT2?	no longer available from ATCC® or by reference strain number	BEI Resources	former ATCC® 43894			

Genus	Species/Serotype	Strain	Source	Additional Recommended Species/Strains			Exclusivity Species
				Species	Strain/Serotype	Source	
	<i>E. coli</i> O157:H7 (EDL 931) Non O157:H7 EHEC strains Shigella STX gene	no longer available from ATCC® or by reference strain number			former ATCC® 35150		
<i>Giardia</i>	<i>G. lamblia</i> <i>G. muris</i>	Human Isolate H3 P101	Waterborne, Inc				
<i>Helicobacter pylori</i>							
<i>Listeria</i>	<i>L. monocytogenes</i> ½ a <i>L. monocytogenes</i> ½ a <i>L. monocytogenes</i> ½ b <i>L. monocytogenes</i> ½ c <i>L. monocytogenes</i> 3a <i>L. monocytogenes</i> 4b <i>L. monocytogenes</i> 4b <i>L. monocytogenes</i> 4d <i>L. monocytogenes</i> <i>L. monocytogenes</i> (non-hemolytic) <i>L. ivanovii</i> 5 <i>L. innocua</i> 6a <i>L. welshimeri</i> 6b <i>L. seeligeri</i> <i>L. grayi</i> <i>L. grayi</i>	ATCC® 51772™ ATCC® 51775™ ATCC® 51780™ ATCC® 51779™ ATCC® 51782™ Scott A ATCC® 19115™ ATCC® 19117™ ATCC® 19111™ ATCC® 15313™ ATCC® 19119™ ATCC® 33090™ ATCC® 35897™ ATCC® 35967™ ATCC® 25400™ ATCC® 25401™	ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC® ATCC®				
<i>Mycobacterium paratuberculosis</i>							
			BEI Resources	Controlled Access Strain			
<i>Norovirus</i>	Norwalk – Group I Snow Mountain Agent – Group II	Any isolates from feces from naturally infected individuals. Currently, no isolate or strain is maintained in a laboratory.					
<i>Salmonella</i>	<i>Salmonella Typhi</i> <i>Salmonella Paratyphi A</i> <i>Salmonella Paratyphi B</i> <i>Salmonella Paratyphi C</i> <i>Salmonella Sendai</i> <i>Salmonella Typhimurium</i> <i>Salmonella Enteritidis</i> <i>Salmonella choleraesuis</i>			Representatives from somatic groups B-I Representatives from "further groups"			
		ATCC® 13311™ ATCC® 13076™ ATCC® 10708™	ATCC® ATCC® ATCC®		H2S negative strain (>48 hours)		
	1. A minimum of 35 of the top 50 serotypes isolated in the United States from 1968 to 1998 (see attached table An Atlas of Salmonella in the United States published by the CDC in 2000.						
	2. Representatives from somatic groups B-I (serotypes should be evenly distributed across the groups). A minimum of 30 serotypes seems appropriate.						
	Representatives from "further groups". These further groups should also include representative serotypes from <i>S. enterica</i> , subspecies <i>salamae</i> (II), <i>arizonae</i> (IIIa), <i>diarizonae</i> (IIIb), <i>houtenae</i> (IV), and <i>indica</i> (VI). <i>S. bongori</i> should also be included if possible.						
<i>Shigella</i>	<i>S. boydii</i> serotype 2 <i>S. dysenteriae</i> <i>S. flexneri</i> serotype 2a <i>S. sonnei</i> WRAIR I virulent	NCTC 12985 NCTC 4837 24570	BEI Resources BEI Resources BEI Resources				
<i>Staphylococcus</i>	<i>S. aureus</i> <i>S. aureus</i> <i>S. epidermidis</i>	ATCC® 25923™ ATCC® 6538™ ATCC® 12228™	ATCC® ATCC® ATCC®				
<i>Staphylococcal Enterotoxins</i>							
	A B C1 C2 C3 D	FRI-722 (FDA) 110-270USAMRIID FRI 137 (FDA) FRI 361 (FDA) FRI 1230 (FDA) FRI 1151 (FDA)	Toxin Technology Toxin Technology Toxin Technology Toxin Technology Toxin Technology Toxin Technology				

Genus	Species/Serotype	Strain	Source	Additional Recommended Species/Strains			Exclusivity Species
				Species	Strain/Serotype	Source	
	E	FRI 326 (FDA)	Toxin Technology				
	F (Toxic shock toxin)	RFDA 485 (A,B,D) (FDA)	Toxin Technology				
	Non-toxigenic strain	FDA D87	FDA				
		FDA D184	FDA				
		<i>S. intermidis</i>	FDA				
<i>Vibrio</i>	<i>V. cholerae</i>	7 th pandemic O1 strain					
	<i>V. cholerae</i>	O139 (7 th pandemic strain that has mutated to have a capsule)					
	<i>V. cholerae</i>	non-O1/non-O139/non-toxigenic strain					
	<i>V. cholerae</i>	Gulf Coast O1 toxigenic strain (non-epidemic)					
	<i>V. cholerae</i>	classical <i>cholerae</i> strain					
	<i>V. cholerae</i>	O141 toxigenic strain that has recently emerged					
	<i>V. parahaemolyticus</i> O3:K6						
	<i>V. parahaemolyticus</i> O4:K12	tdh+/trh+					
	<i>V. parahaemolyticus</i>	non-pathogenic strain (tdh-/trh-)					
	<i>V. parahaemolyticus</i>	clinical strain (tdh-/trh+)					
	<i>V. vulnificus</i> , biotype 1 (rRNA type B)						
	<i>V. vulnificus</i> , biotype 2 (rRNA type A)						
	<i>V. vulnificus</i> biotype 3 (rRNA type A/B)						
<i>Yersinia</i>	<i>Y. enterocolitica</i>	ATCC® 27729™	ATCC®				

* This table presents a reasonably comprehensive inclusivity list of reference pathogenic and related microbiological species and toxins that must be included in any validations study.

Other strains used for inclusivity or exclusivity must be characterized using nationally or internationally accepted reference methods.

The pre-collaborative and/or collaborative study protocols submitted by method developers or study directors for review, will be evaluated by an expert panel to ensure that the strains selected for exclusivity include a sufficient number of appropriate "nearest-neighbours" to also challenge the inclusivity of the method.